vs

Side-by-side financial comparison of Eventbrite, Inc. (EB) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $73.5M, roughly 1.0× Eventbrite, Inc.). On growth, Eventbrite, Inc. posted the faster year-over-year revenue change (-3.9% vs -36.9%). MEDIFAST INC produced more free cash flow last quarter ($-6.6M vs $-60.9M). Over the past eight quarters, Eventbrite, Inc.'s revenue compounded faster (-7.7% CAGR vs -34.4%).

Eventbrite is an American live events marketplace and website. The service allows users to browse, create, and promote local events. It is free to publish unlimited events of any size on Eventbrite.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

EB vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.0× larger
MED
$75.1M
$73.5M
EB
Growing faster (revenue YoY)
EB
EB
+33.0% gap
EB
-3.9%
-36.9%
MED
More free cash flow
MED
MED
$54.2M more FCF
MED
$-6.6M
$-60.9M
EB
Faster 2-yr revenue CAGR
EB
EB
Annualised
EB
-7.7%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EB
EB
MED
MED
Revenue
$73.5M
$75.1M
Net Profit
$-8.2M
Gross Margin
68.1%
69.4%
Operating Margin
-12.4%
-10.4%
Net Margin
-11.1%
Revenue YoY
-3.9%
-36.9%
Net Profit YoY
2.5%
EPS (diluted)
$-0.08
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EB
EB
MED
MED
Q4 25
$73.5M
$75.1M
Q3 25
$71.7M
$89.4M
Q2 25
$72.8M
$105.6M
Q1 25
$73.8M
$115.7M
Q4 24
$76.5M
$119.0M
Q3 24
$77.8M
$140.2M
Q2 24
$84.6M
$168.6M
Q1 24
$86.3M
$174.7M
Net Profit
EB
EB
MED
MED
Q4 25
$-8.2M
Q3 25
$6.4M
$-2.3M
Q2 25
$-2.1M
$2.5M
Q1 25
$-6.6M
$-772.0K
Q4 24
$-8.4M
Q3 24
$-3.8M
$1.1M
Q2 24
$1.1M
$-8.2M
Q1 24
$-4.5M
$8.3M
Gross Margin
EB
EB
MED
MED
Q4 25
68.1%
69.4%
Q3 25
67.9%
69.5%
Q2 25
67.5%
72.6%
Q1 25
66.9%
72.8%
Q4 24
68.2%
74.1%
Q3 24
68.5%
75.4%
Q2 24
70.9%
73.2%
Q1 24
71.0%
72.8%
Operating Margin
EB
EB
MED
MED
Q4 25
-12.4%
-10.4%
Q3 25
-1.3%
-4.6%
Q2 25
-8.7%
-1.0%
Q1 25
-13.2%
-1.1%
Q4 24
-10.2%
0.6%
Q3 24
-11.5%
1.5%
Q2 24
-7.6%
-4.7%
Q1 24
-8.8%
4.5%
Net Margin
EB
EB
MED
MED
Q4 25
-11.1%
Q3 25
8.9%
-2.5%
Q2 25
-2.9%
2.3%
Q1 25
-9.0%
-0.7%
Q4 24
-11.0%
Q3 24
-4.8%
0.8%
Q2 24
1.3%
-4.8%
Q1 24
-5.2%
4.8%
EPS (diluted)
EB
EB
MED
MED
Q4 25
$-0.08
$-1.64
Q3 25
$0.06
$-0.21
Q2 25
$-0.02
$0.22
Q1 25
$-0.07
$-0.07
Q4 24
$-0.09
$0.08
Q3 24
$-0.04
$0.10
Q2 24
$0.01
$-0.75
Q1 24
$-0.05
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EB
EB
MED
MED
Cash + ST InvestmentsLiquidity on hand
$299.9M
$167.3M
Total DebtLower is stronger
$144.4M
Stockholders' EquityBook value
$179.1M
$198.9M
Total Assets
$647.2M
$248.0M
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EB
EB
MED
MED
Q4 25
$299.9M
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$441.5M
$162.3M
Q3 24
$24.7M
$170.0M
Q2 24
$56.7M
$163.5M
Q1 24
$113.7M
$156.4M
Total Debt
EB
EB
MED
MED
Q4 25
$144.4M
Q3 25
$174.9M
Q2 25
$241.3M
Q1 25
$241.0M
Q4 24
$240.7M
Q3 24
$240.4M
Q2 24
$358.7M
Q1 24
$358.2M
Stockholders' Equity
EB
EB
MED
MED
Q4 25
$179.1M
$198.9M
Q3 25
$189.1M
$214.7M
Q2 25
$177.2M
$216.0M
Q1 25
$173.3M
$211.0M
Q4 24
$170.2M
$210.1M
Q3 24
$179.8M
$207.3M
Q2 24
$176.2M
$205.3M
Q1 24
$184.1M
$211.0M
Total Assets
EB
EB
MED
MED
Q4 25
$647.2M
$248.0M
Q3 25
$744.6M
$268.2M
Q2 25
$784.1M
$269.3M
Q1 25
$812.3M
$280.0M
Q4 24
$752.3M
$284.2M
Q3 24
$817.4M
$291.2M
Q2 24
$894.5M
$293.5M
Q1 24
$952.2M
$302.8M
Debt / Equity
EB
EB
MED
MED
Q4 25
0.81×
Q3 25
0.92×
Q2 25
1.36×
Q1 25
1.39×
Q4 24
1.41×
Q3 24
1.34×
Q2 24
2.04×
Q1 24
1.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EB
EB
MED
MED
Operating Cash FlowLast quarter
$-60.8M
$-5.3M
Free Cash FlowOCF − Capex
$-60.9M
$-6.6M
FCF MarginFCF / Revenue
-82.8%
-8.8%
Capex IntensityCapex / Revenue
0.0%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$17.6M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EB
EB
MED
MED
Q4 25
$-60.8M
$-5.3M
Q3 25
$36.7M
$12.1M
Q2 25
$-17.5M
$-3.4M
Q1 25
$59.4M
$3.4M
Q4 24
$-45.3M
$-4.9M
Q3 24
$44.6M
$9.1M
Q2 24
$-32.3M
$13.1M
Q1 24
$68.6M
$7.3M
Free Cash Flow
EB
EB
MED
MED
Q4 25
$-60.9M
$-6.6M
Q3 25
$36.6M
$10.8M
Q2 25
$-17.5M
$-4.8M
Q1 25
$59.4M
$1.9M
Q4 24
$-45.3M
$-7.2M
Q3 24
$44.4M
$7.7M
Q2 24
$-32.4M
$11.1M
Q1 24
$68.2M
$5.4M
FCF Margin
EB
EB
MED
MED
Q4 25
-82.8%
-8.8%
Q3 25
51.1%
12.0%
Q2 25
-24.1%
-4.5%
Q1 25
80.4%
1.6%
Q4 24
-59.2%
-6.1%
Q3 24
57.1%
5.5%
Q2 24
-38.3%
6.6%
Q1 24
79.1%
3.1%
Capex Intensity
EB
EB
MED
MED
Q4 25
0.0%
1.8%
Q3 25
0.0%
1.5%
Q2 25
0.0%
1.3%
Q1 25
0.1%
1.3%
Q4 24
0.0%
1.9%
Q3 24
0.2%
1.0%
Q2 24
0.1%
1.1%
Q1 24
0.4%
1.1%
Cash Conversion
EB
EB
MED
MED
Q4 25
Q3 25
5.76×
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
-30.37×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EB
EB

US$52.0M71%
Other$21.6M29%

MED
MED

Segment breakdown not available.

Related Comparisons